The Cooper Companies, Inc. (COO) slumps on Q3 miss
The Cooper Companies, Inc. (COO) slumps after hours after fiscal Q3 results showed an EPS beat but a revenue miss and softer Q4 guidance. Investors are reacting to slowing sales growth and a premium valuation, which could keep pressure on the stock if the decline holds into regular trading.
The Cooper Companies, Inc. (COO) slumps sharply after reporting fiscal Q3 results that beat on adjusted EPS but missed on revenue and pointed to weaker-than-expected Q4 sales. The market is punishing the stock because growth slowed to just 1% and guidance fell short of consensus, a tough combination for a high-valuation name. For investors, the key issue now is whether COO can reaccelerate revenue growth enough to justify its premium multiple.
The Cooper Companies, Inc. (COO) slumps 16.07% in after-hours trading after a fiscal Q3 report that delivered an EPS beat but a revenue miss. At 6:04 p.m. ET on Sept. 9, 2026, the stock printed $53.28, down from the $63.48 regular-session close. Because this is an extended-hours move, regular-session trading will confirm whether the decline holds.
Key Takeaways
COO fell 16.07% after-hours following its fiscal Q3 2026 earnings report.
Adjusted EPS reached $1.15 versus a $1.11 estimate, but revenue rose only 1% to about $1.066B.
Q3 revenue missed estimates by $30M, according to post-earnings coverage.
Fourth-quarter revenue guidance of $1.057B to $1.080B came below the $1.11B consensus estimate.
The $12.38B company trades at a 57.4 P/E, leaving little room for a slowdown in growth.
What's Behind The Cooper Companies (COO) After-Hours Selloff
The specific catalyst is fiscal Q3 2026 earnings, reported on Sept. 9 after the regular session. Trading activity supports that conclusion. COO moved between $68.65 and $50.72 during the day, while volume reached roughly 9.4 million shares.
That combination points to an earnings-driven repricing rather than a routine sector move. Recent analyst records also do not show a fresh downgrade driving the decline. Citigroup reaffirmed a Hold rating on Aug. 13, while the sharpest recent price-target changes occurred in June.
The earnings details explain why the reaction turned negative despite higher profit. Adjusted EPS increased to $1.15 from $1.10 a year earlier. However, revenue reached only about $1.066B, up 1% year over year and below the roughly $1.10B estimate cited before the report.
In other words, the headline EPS result was positive, but sales momentum disappointed. Markets often punish that mix when a company carries a premium valuation. A modest profit beat cannot fully offset evidence that demand or growth is slowing.
Why COO's Revenue Miss Matters More Than Its EPS Beat
Revenue growth is the central issue in this selloff. Pre-earnings coverage cited a prior-quarter revenue result of $1.08B, up 7.9% year over year. The latest quarter's 1% increase therefore marks a sharp deceleration in the reported growth rate.
The fourth-quarter outlook added pressure. CooperCompanies set total revenue guidance at $1.057B to $1.080B, compared with a $1.11B consensus estimate. That range tells the market that near-term sales could remain below the pace analysts had modeled.
The company also provided fiscal 2026 guidance of $4.51 to $4.55 in adjusted EPS and $4.23B to $4.25B in revenue. Those figures provide a financial anchor, but they do not erase the weaker quarterly sales signal. The market is focusing on the quality and speed of growth, not just whether earnings cleared an estimate.
This distinction matters because EPS can rise through product mix, pricing, or cost control even when sales growth slows. For COO, the 1% revenue increase and below-consensus Q4 range create a more serious concern than the $1.15 EPS beat resolves.
How The Cooper Companies' Valuation Raises the Stakes
CooperCompanies operates two distinct businesses. CooperVision sells spherical, toric, and multifocal contact lenses, including products for astigmatism, presbyopia, and myopia. CooperSurgical serves fertility, women's health, medical device, and contraception markets.
That portfolio gives COO exposure to recurring contact lens demand, premium and specialty products, myopia management, and fertility-related procedures. However, those businesses do not move in lockstep. Contact lens replacement demand can be steady, while fertility and women's health volumes can be more uneven.
The valuation made the earnings reaction more severe. COO had a market capitalization of $12.38B and a P/E of 57.4 before this after-hours reset. A multiple at that level requires investors to believe that the company can sustain strong, dependable earnings growth.
Instead, the latest report showed 1% revenue growth and a Q4 sales range below consensus. The after-hours price of $53.28 also sits below the listed 52-week low of $58.89. That price action signals a sharp change in how the market values COO's growth profile.
What COO Investors Can Measure After the Earnings Reset
A disciplined framework starts with revenue rather than EPS. The key figures are the $1.066B Q3 result, 1% year-over-year growth, and the $1.057B to $1.080B Q4 guidance range. Together, they define the near-term growth hurdle.
Next, separate business quality from stock valuation. COO still has focused positions in contact lenses, fertility, and women's health. Yet a strong competitive position does not guarantee a strong return when the market has priced in faster expansion.
The 57.4 P/E provides a simple risk test. If revenue growth stays near 1%, the market could compress the multiple even if adjusted EPS remains positive. If sales regain the mid-single-digit pace cited in the company's broader investment narrative, the valuation pressure could ease.
Analyst sentiment also needs careful interpretation. The latest consensus shows 16 Buy ratings, 8 Holds, and 1 Sell. That positive rating mix can support a rebound, but it does not cancel the immediate revenue miss or the weaker Q4 sales outlook.
Finally, after-hours prices deserve restraint. The $53.28 print captures the first reaction to the report, while regular-session liquidity will provide a broader test of demand. A sustained move below the prior $63.48 close would keep the earnings reset in focus.
COO's after-hours slump is an earnings reset driven by weak revenue growth and Q4 guidance below consensus, not by a failure to produce adjusted EPS growth. The business remains positioned in recurring contact lenses and specialized women's health markets, but the 57.4 P/E makes a 1% sales increase difficult for investors to accept.
The practical takeaway is to judge COO on revenue acceleration and valuation discipline. Regular-session trading will show whether the market treats this decline as an overreaction or as a lasting downgrade to the company's growth outlook.
COO stock is down because the company posted a fiscal Q3 revenue miss and issued Q4 revenue guidance below Wall Street expectations. Even though adjusted EPS beat estimates, investors focused on slowing sales growth and sold the stock after hours.
+Should I buy COO stock now?
Not aggressively based on this report alone. The stock's premium valuation looks harder to justify after 1% revenue growth and weaker guidance, so investors may want to wait for signs of sales reacceleration.
+Did The Cooper Companies beat earnings?
Yes, The Cooper Companies beat adjusted EPS estimates with $1.15 versus the $1.11 consensus. But the earnings beat was outweighed by a revenue miss and softer forward guidance.
+What is the main risk for COO investors after this report?
The main risk is that revenue growth stays too slow to support the stock's high valuation. If sales do not improve, the market could continue to compress COO's multiple even if profits remain solid.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on COO?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
